ECSP13012698A - Derivados de imidazol como inhibidores de la enzima pde10a - Google Patents
Derivados de imidazol como inhibidores de la enzima pde10aInfo
- Publication number
- ECSP13012698A ECSP13012698A ECSP13012698A ECSP13012698A EC SP13012698 A ECSP13012698 A EC SP13012698A EC SP13012698 A ECSP13012698 A EC SP13012698A EC SP13012698 A ECSP13012698 A EC SP13012698A
- Authority
- EC
- Ecuador
- Prior art keywords
- provides
- subject
- compound
- formula
- effective amount
- Prior art date
Links
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 4
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Esta invención se refiere a compuestos (I) que son inhibidores de la enzima PDE10A. La invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto de la invención y un portador farmacéuticamente aceptable. La presente invención proporciona asimismo procesos para usar en la preparación de los compuestos de fórmula I. La presente invención proporciona asimismo un método para tratar un sujeto que padece un trastorno neurodegenerativo que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de fórmula I. La presente invención proporciona asimismo un método para tratar a un sujeto que sufre de una adicción a sustancias, que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de fórmula I. La presente invención proporciona asimismo un método para tratar a un sujeto que padece un trastorno psiquiátrico, que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de fórmula I.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201001045 | 2010-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012698A true ECSP13012698A (es) | 2013-08-30 |
Family
ID=45217102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012698 ECSP13012698A (es) | 2010-11-19 | 2013-06-18 | Derivados de imidazol como inhibidores de la enzima pde10a |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP2640731B9 (es) |
| JP (1) | JP5937608B2 (es) |
| KR (1) | KR101916487B1 (es) |
| CN (1) | CN103328487B (es) |
| AP (1) | AP3342A (es) |
| AR (1) | AR083926A1 (es) |
| AU (1) | AU2011331607B2 (es) |
| BR (1) | BR112013012378A2 (es) |
| CA (1) | CA2817663C (es) |
| CR (1) | CR20130226A (es) |
| DK (1) | DK2640731T3 (es) |
| EA (1) | EA027082B1 (es) |
| EC (1) | ECSP13012698A (es) |
| ES (1) | ES2547090T3 (es) |
| GE (1) | GEP20156346B (es) |
| GT (1) | GT201300130A (es) |
| HU (1) | HUE025596T2 (es) |
| JO (1) | JO3089B1 (es) |
| ME (1) | ME02193B (es) |
| MY (1) | MY163327A (es) |
| NZ (1) | NZ610353A (es) |
| PE (1) | PE20141534A1 (es) |
| PH (1) | PH12013500968A1 (es) |
| PL (1) | PL2640731T3 (es) |
| PT (1) | PT2640731E (es) |
| RS (1) | RS54210B1 (es) |
| SG (1) | SG190282A1 (es) |
| SI (1) | SI2640731T1 (es) |
| TW (1) | TWI541245B (es) |
| UA (1) | UA112065C2 (es) |
| WO (1) | WO2012065612A1 (es) |
| ZA (1) | ZA201303607B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8552045B2 (en) | 2010-11-19 | 2013-10-08 | H. Lundbeck A/S | Tricyclic imidazole compounds as PDE10 inhibitors |
| US8765760B2 (en) * | 2011-01-11 | 2014-07-01 | Sunovion Pharmaceuticals, Inc. | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases |
| WO2013045607A1 (en) * | 2011-09-30 | 2013-04-04 | H. Lundbeck A/S | Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors |
| WO2013107856A1 (en) * | 2012-01-20 | 2013-07-25 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
| EP2861596B1 (en) * | 2012-06-19 | 2019-03-20 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| CN103435617B (zh) * | 2013-08-22 | 2016-04-27 | 南京华安药业有限公司 | 一种6,7-二氢-5H-吡咯并[1,2-a]咪唑-2-甲醛的合成方法 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| WO2018073251A1 (en) | 2016-10-18 | 2018-04-26 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| AU2017350473A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| WO2018078042A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| BR112020013820A2 (pt) | 2018-11-06 | 2021-06-01 | H. Lundbeck A/S | inibidores de pde10a para tratamento de sintomas negativos e comprometimentos cognitivos em um paciente sofrendo de esquizofrenia |
| CN109776527A (zh) * | 2019-02-21 | 2019-05-21 | 药雅科技(上海)有限公司 | 一种5-溴-7-氮杂吲哚的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8307865D0 (en) | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
| US5571775A (en) | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
| RS20050945A (sr) | 2003-06-30 | 2008-06-05 | Altana Pharma Ag., | Novi pirolodihidroizohinolini koji se mogu upotrebiti u tretmanu kancera |
| US20070105840A1 (en) | 2003-06-30 | 2007-05-10 | Altana Pharma Ag | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
| EP1723134A2 (en) | 2004-02-18 | 2006-11-22 | Pfizer Products Incorporated | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
| EP1755611A1 (en) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| CA2578996A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US8133897B2 (en) | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
| CA2765750A1 (en) * | 2009-06-19 | 2010-12-23 | H. Lundbeck A/S | Novel phenylimidazole derivative as pde10a enzyme inhibitor |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TW201200516A (en) * | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
| TWI485151B (zh) * | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
-
2011
- 2011-11-14 JO JOP/2011/0339A patent/JO3089B1/ar active
- 2011-11-15 TW TW100141570A patent/TWI541245B/zh not_active IP Right Cessation
- 2011-11-18 HU HUE11793325A patent/HUE025596T2/en unknown
- 2011-11-18 DK DK11793325.9T patent/DK2640731T3/en active
- 2011-11-18 PH PH1/2013/500968A patent/PH12013500968A1/en unknown
- 2011-11-18 RS RS20150574A patent/RS54210B1/sr unknown
- 2011-11-18 PT PT117933259T patent/PT2640731E/pt unknown
- 2011-11-18 UA UAA201307630A patent/UA112065C2/uk unknown
- 2011-11-18 SG SG2013037163A patent/SG190282A1/en unknown
- 2011-11-18 WO PCT/DK2011/000136 patent/WO2012065612A1/en not_active Ceased
- 2011-11-18 JP JP2013539140A patent/JP5937608B2/ja not_active Expired - Fee Related
- 2011-11-18 KR KR1020137012797A patent/KR101916487B1/ko not_active Expired - Fee Related
- 2011-11-18 PE PE2013001212A patent/PE20141534A1/es active IP Right Grant
- 2011-11-18 AP AP2013006928A patent/AP3342A/xx active
- 2011-11-18 SI SI201130586T patent/SI2640731T1/sl unknown
- 2011-11-18 CA CA2817663A patent/CA2817663C/en not_active Expired - Fee Related
- 2011-11-18 GE GEAP201113117A patent/GEP20156346B/en unknown
- 2011-11-18 BR BR112013012378A patent/BR112013012378A2/pt not_active Application Discontinuation
- 2011-11-18 CN CN201180065325.2A patent/CN103328487B/zh not_active Expired - Fee Related
- 2011-11-18 MY MYPI2013001727A patent/MY163327A/en unknown
- 2011-11-18 EA EA201390741A patent/EA027082B1/ru not_active IP Right Cessation
- 2011-11-18 NZ NZ610353A patent/NZ610353A/en not_active IP Right Cessation
- 2011-11-18 PL PL11793325T patent/PL2640731T3/pl unknown
- 2011-11-18 ES ES11793325.9T patent/ES2547090T3/es active Active
- 2011-11-18 ME MEP-2015-130A patent/ME02193B/me unknown
- 2011-11-18 AR ARP110104313A patent/AR083926A1/es unknown
- 2011-11-18 EP EP11793325.9A patent/EP2640731B9/en active Active
- 2011-11-18 AU AU2011331607A patent/AU2011331607B2/en not_active Ceased
-
2013
- 2013-05-16 GT GT201300130A patent/GT201300130A/es unknown
- 2013-05-16 CR CR20130226A patent/CR20130226A/es unknown
- 2013-05-17 ZA ZA2013/03607A patent/ZA201303607B/en unknown
- 2013-06-18 EC ECSP13012698 patent/ECSP13012698A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012698A (es) | Derivados de imidazol como inhibidores de la enzima pde10a | |
| CO6321263A2 (es) | Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a | |
| ECSP14015609A (es) | Inhibidores de pde9 con estructura básica de imidazotriazinona | |
| CR20120319A (es) | Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a | |
| DOP2012000168A (es) | Derivados de 2-arimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| IN2015DN02829A (es) | ||
| MX2012006715A (es) | Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a. | |
| DOP2013000108A (es) | Derivados de imidazol como inhibidores de la enzima pde10a | |
| CY1116689T1 (el) | Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a | |
| TN2013000200A1 (en) | Imidazole derivatives as pde 10a enzyme inhibitors | |
| UA102693C2 (ru) | Производные фенилимидазола как ингибиторы фермента pde10a |